ST
Solve Therapeutics, Inc.
SEC filingBiotechnology · Belmont, CA
Amount raised$48.2Msold at filing
Total offering$120.5M$72.3M still open
Investors in the raise16count reported to the SEC
FiledNov 25, 2025first sale Nov 14, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Daniel D. McHughDirector
Langdon MillerExecutive Officer
David JohnsonExecutive Officer, Director
Clayton D. KnoxExecutive Officer
Robert D. MittendorffDirector
Alan ColowickDirector
Jason PittsDirector
Peter ColabuonoDirector
Executive officers, directors and promoters as listed on the Form D.